Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

Hak Choy, Yu Shyr, Anthony J. Cmelak, Peter J. Mohr, David H. Johnson

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BACKGROUND. Nonsmall cell lung carcinoma comprises approximately 75% of all lung carcinoma cases in the U.S. Newly evolving strategies have created considerable controversy regarding the optimal treatment for patients diagnosed with this disease. METHODS. A 17-item survey was designed to collect demographic data and information regarding practice patterns for nonsmall cell lung carcinoma, including patient assessment, treatment approaches, and roles of chemotherapy and radiotherapy. Surveys were mailed in the summer of 1997 to approximately 9200 oncologists of all types throughout the U.S. Practice settings included private office, private hospital, academic, university-affiliated office, government, and Veterans Administration institutions. RESULTS. Approximately 10% of the oncologists responded (n = 979), including 499 medical oncologists (51%), 464 radiation oncologists (47%), and 16 others (2%). For the adjuvant treatment of surgically resected N1-2 disease, combined modality treatment was preferred over radiation therapy alone by medical oncologists (48% vs. 16%; P < 0.001) and radiation therapy alone was preferred over combined modality treatment by radiation oncologists (55% vs. 38%; P < 0,001). The combination of paclitaxel and carboplatin was the preferred first-line regimen for all stages of nonsmall cell lung carcinoma by the majority of medical oncologists (55%), whereas the majority of radiation oncologists (58%) chose the combination of etoposide and platinum. With regard to the optimal combined modality approach, respondents were divided evenly between concurrent chemoradiotherapy (34%) and sequential chemoradiotherapy (31%). Overall, respondents reported basing treatment decisions largely on published literature (55%) compared with personal experience (19%), seminars and colleagues (16%), and clinical trial availability (10%) (P < 0.001). CONCLUSIONS. This survey confirms many differences in practice patterns among medical oncologists and radiation oncologists in the treatment of patients with nonsmall cell lung carcinoma and suggests the need for the multidisciplinary management of this entity. In addition, the current study demonstrates that reliance on the medical literature as a basis for treatment steadily declines the longer the physician has been in practice. (C) 2000 American Cancer Society.

Original languageEnglish (US)
Pages (from-to)1336-1346
Number of pages11
JournalCancer
Volume88
Issue number6
DOIs
StatePublished - Mar 15 2000

Fingerprint

Carcinoma
Lung
Radiotherapy
Chemoradiotherapy
Therapeutics
United States Department of Veterans Affairs
Private Hospitals
Surveys and Questionnaires
Carboplatin
Etoposide
Paclitaxel
Platinum
Oncologists
Demography
Clinical Trials
Physicians
Drug Therapy
Radiation Oncologists

Keywords

  • Combined modality
  • Data collection
  • Nonsmall cell lung carcinoma (NSCLC)
  • Practice patterns
  • Questionnaires

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. / Choy, Hak; Shyr, Yu; Cmelak, Anthony J.; Mohr, Peter J.; Johnson, David H.

In: Cancer, Vol. 88, No. 6, 15.03.2000, p. 1336-1346.

Research output: Contribution to journalArticle

Choy, Hak ; Shyr, Yu ; Cmelak, Anthony J. ; Mohr, Peter J. ; Johnson, David H. / Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. In: Cancer. 2000 ; Vol. 88, No. 6. pp. 1336-1346.
@article{71b5436b9d734b52a9ffc16dde44dce7,
title = "Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.",
abstract = "BACKGROUND. Nonsmall cell lung carcinoma comprises approximately 75{\%} of all lung carcinoma cases in the U.S. Newly evolving strategies have created considerable controversy regarding the optimal treatment for patients diagnosed with this disease. METHODS. A 17-item survey was designed to collect demographic data and information regarding practice patterns for nonsmall cell lung carcinoma, including patient assessment, treatment approaches, and roles of chemotherapy and radiotherapy. Surveys were mailed in the summer of 1997 to approximately 9200 oncologists of all types throughout the U.S. Practice settings included private office, private hospital, academic, university-affiliated office, government, and Veterans Administration institutions. RESULTS. Approximately 10{\%} of the oncologists responded (n = 979), including 499 medical oncologists (51{\%}), 464 radiation oncologists (47{\%}), and 16 others (2{\%}). For the adjuvant treatment of surgically resected N1-2 disease, combined modality treatment was preferred over radiation therapy alone by medical oncologists (48{\%} vs. 16{\%}; P < 0.001) and radiation therapy alone was preferred over combined modality treatment by radiation oncologists (55{\%} vs. 38{\%}; P < 0,001). The combination of paclitaxel and carboplatin was the preferred first-line regimen for all stages of nonsmall cell lung carcinoma by the majority of medical oncologists (55{\%}), whereas the majority of radiation oncologists (58{\%}) chose the combination of etoposide and platinum. With regard to the optimal combined modality approach, respondents were divided evenly between concurrent chemoradiotherapy (34{\%}) and sequential chemoradiotherapy (31{\%}). Overall, respondents reported basing treatment decisions largely on published literature (55{\%}) compared with personal experience (19{\%}), seminars and colleagues (16{\%}), and clinical trial availability (10{\%}) (P < 0.001). CONCLUSIONS. This survey confirms many differences in practice patterns among medical oncologists and radiation oncologists in the treatment of patients with nonsmall cell lung carcinoma and suggests the need for the multidisciplinary management of this entity. In addition, the current study demonstrates that reliance on the medical literature as a basis for treatment steadily declines the longer the physician has been in practice. (C) 2000 American Cancer Society.",
keywords = "Combined modality, Data collection, Nonsmall cell lung carcinoma (NSCLC), Practice patterns, Questionnaires",
author = "Hak Choy and Yu Shyr and Cmelak, {Anthony J.} and Mohr, {Peter J.} and Johnson, {David H.}",
year = "2000",
month = "3",
day = "15",
doi = "10.1002/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M",
language = "English (US)",
volume = "88",
pages = "1336--1346",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

AU - Choy, Hak

AU - Shyr, Yu

AU - Cmelak, Anthony J.

AU - Mohr, Peter J.

AU - Johnson, David H.

PY - 2000/3/15

Y1 - 2000/3/15

N2 - BACKGROUND. Nonsmall cell lung carcinoma comprises approximately 75% of all lung carcinoma cases in the U.S. Newly evolving strategies have created considerable controversy regarding the optimal treatment for patients diagnosed with this disease. METHODS. A 17-item survey was designed to collect demographic data and information regarding practice patterns for nonsmall cell lung carcinoma, including patient assessment, treatment approaches, and roles of chemotherapy and radiotherapy. Surveys were mailed in the summer of 1997 to approximately 9200 oncologists of all types throughout the U.S. Practice settings included private office, private hospital, academic, university-affiliated office, government, and Veterans Administration institutions. RESULTS. Approximately 10% of the oncologists responded (n = 979), including 499 medical oncologists (51%), 464 radiation oncologists (47%), and 16 others (2%). For the adjuvant treatment of surgically resected N1-2 disease, combined modality treatment was preferred over radiation therapy alone by medical oncologists (48% vs. 16%; P < 0.001) and radiation therapy alone was preferred over combined modality treatment by radiation oncologists (55% vs. 38%; P < 0,001). The combination of paclitaxel and carboplatin was the preferred first-line regimen for all stages of nonsmall cell lung carcinoma by the majority of medical oncologists (55%), whereas the majority of radiation oncologists (58%) chose the combination of etoposide and platinum. With regard to the optimal combined modality approach, respondents were divided evenly between concurrent chemoradiotherapy (34%) and sequential chemoradiotherapy (31%). Overall, respondents reported basing treatment decisions largely on published literature (55%) compared with personal experience (19%), seminars and colleagues (16%), and clinical trial availability (10%) (P < 0.001). CONCLUSIONS. This survey confirms many differences in practice patterns among medical oncologists and radiation oncologists in the treatment of patients with nonsmall cell lung carcinoma and suggests the need for the multidisciplinary management of this entity. In addition, the current study demonstrates that reliance on the medical literature as a basis for treatment steadily declines the longer the physician has been in practice. (C) 2000 American Cancer Society.

AB - BACKGROUND. Nonsmall cell lung carcinoma comprises approximately 75% of all lung carcinoma cases in the U.S. Newly evolving strategies have created considerable controversy regarding the optimal treatment for patients diagnosed with this disease. METHODS. A 17-item survey was designed to collect demographic data and information regarding practice patterns for nonsmall cell lung carcinoma, including patient assessment, treatment approaches, and roles of chemotherapy and radiotherapy. Surveys were mailed in the summer of 1997 to approximately 9200 oncologists of all types throughout the U.S. Practice settings included private office, private hospital, academic, university-affiliated office, government, and Veterans Administration institutions. RESULTS. Approximately 10% of the oncologists responded (n = 979), including 499 medical oncologists (51%), 464 radiation oncologists (47%), and 16 others (2%). For the adjuvant treatment of surgically resected N1-2 disease, combined modality treatment was preferred over radiation therapy alone by medical oncologists (48% vs. 16%; P < 0.001) and radiation therapy alone was preferred over combined modality treatment by radiation oncologists (55% vs. 38%; P < 0,001). The combination of paclitaxel and carboplatin was the preferred first-line regimen for all stages of nonsmall cell lung carcinoma by the majority of medical oncologists (55%), whereas the majority of radiation oncologists (58%) chose the combination of etoposide and platinum. With regard to the optimal combined modality approach, respondents were divided evenly between concurrent chemoradiotherapy (34%) and sequential chemoradiotherapy (31%). Overall, respondents reported basing treatment decisions largely on published literature (55%) compared with personal experience (19%), seminars and colleagues (16%), and clinical trial availability (10%) (P < 0.001). CONCLUSIONS. This survey confirms many differences in practice patterns among medical oncologists and radiation oncologists in the treatment of patients with nonsmall cell lung carcinoma and suggests the need for the multidisciplinary management of this entity. In addition, the current study demonstrates that reliance on the medical literature as a basis for treatment steadily declines the longer the physician has been in practice. (C) 2000 American Cancer Society.

KW - Combined modality

KW - Data collection

KW - Nonsmall cell lung carcinoma (NSCLC)

KW - Practice patterns

KW - Questionnaires

UR - http://www.scopus.com/inward/record.url?scp=0034653830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034653830&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M

DO - 10.1002/(SICI)1097-0142(20000315)88:6<1336::AID-CNCR9>3.0.CO;2-M

M3 - Article

C2 - 10717614

AN - SCOPUS:0034653830

VL - 88

SP - 1336

EP - 1346

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -